Factor XI inhibiTion for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty

Phase

Condition

Venous Thromboembolism

Venous Thrombosis

Thromboembolism

Treatment

KN060 Low

KN060 Middle

Enoxaparin

Clinical Study ID

NCT06180889

KN060-A-201

Ages 18-75
All Genders

Study Summary

This study was to compare the study drug KN060 to enoxaparin, for the prevention of blood clotting and safety in patients undergoing total knee arthroplasty (TKA).

Eligibility Criteria

Inclusion

Inclusion Criteria:

Male or female, aged between 18 and 75 years old (including the cut-off value);
undergoing unilateral Total Knee Arthroplasty (TKA);
Voluntarily participate in the study and sign a written informed consent;

Exclusion

Exclusion Criteria:

There is a high risk of bleeding or abnormal bleeding related indicators:
Evidence of venous thrombosis, such as the presence of related symptoms or auxiliarytests indicating thrombosis; Or have a history of venous embolic disease.
Acute myocardial infarction or ischemic stroke occurred within 6 months beforescreening.
Presence of malignant tumors or history of malignant tumors.

Study Design